SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is surging as renewed missile strikes between the U.S. and Iran dissolve hopes for a swift diplomatic resolution and ignite fresh supply concerns. The community is actively debating whether these price swings represent a sustainable rally or another temporary volatility spike driven by diplomatic rhetoric and algorithmic manipulation.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors react to the company's expansion into treatment-resistant schizophrenia, strengthening its pipeline and reinforcing its valuation as a multi-indication biotechnology company. The community is actively debating the company's potential for a lucrative buyout, with many long-term shareholders highlighting the drug's strong market share growth and the strategic value of upcoming clinical milestones.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors weigh the stock's significant long-term potential in the rare earth minerals sector against frustrations regarding project delays and management communication. The community is actively debating the impact of upcoming pilot plant results and the company's involvement in global supply chain initiatives.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion Technologies is currently experiencing high volatility as investors weigh the stock's Ethereum treasury strategy against the stalled status of the Crypto Clarity Act. Community sentiment remains deeply divided, with significant debate occurring between retail traders optimistic about share buybacks and long-term crypto growth and skeptics concerned about valuation and the lack of legislative progress.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is trending as investors digest upbeat quarterly guidance and ongoing pipeline developments, with the stock recently seeing a breakout and increased options activity. Community members are actively debating the company's long-term growth prospects against generic competition and speculating on potential M&A activity within the oncology and immunology sectors.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending due to reports of a potential $400 billion merger with Bristol Myers Squibb to create an oncology powerhouse, a move sparking heavy community discussion about portfolio synergies in cancer treatment and significant antitrust regulatory hurdles. Investors are closely monitoring how this consolidation could reshuffle global R&D dominance, while traders analyze technical breakout levels as institutional liquidity reacts to the rumors.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is currently a major focus for investors as the community anticipates the imminent release of Phase 3 top-line data for its lead oncology asset, with heightened interest surrounding recent institutional buying from major firms like Vanguard. The conversation is dominated by intense debates between bulls betting on a transformative buyout and bears highlighting the stock's long-term underperformance and regulatory hurdles.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing intense market volatility, driven by community debate surrounding potential legislative catalysts like the Clarity Act and concerns over recent high-profile wallet security breaches. Traders remain deeply divided, with many actively debating whether the current price action signals a cyclical bottom or the beginning of a deeper correction.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense scrutiny and volatility as community members debate management's capital allocation strategy, specifically the decision to authorize Bitcoin sales to pay down debt and support preferred stock. Investors are polarized, with some bulls viewing the company as a key leveraged play on Bitcoin's long-term potential, while bears focus on dilution risks, poor earnings performance, and the sustainability of the company's treasury model.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing heightened volatility as investors weigh the uncertain passage of the Clarity Act against broader macroeconomic concerns. The community is actively debating whether current price action represents a major accumulation phase or a prolonged liquidity trap driven by institutional market manipulation.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS

New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS PR Newswire SINGAPORE, Aug. 2, 2026 Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is the first...

Here's Why Incyte (INCY) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod

Equity

The European Commission on Wednesday approved Incyte’s Opzelura cream as the first steroid-free topical treatment of its kind for adults with moderate eczema who do not get enough relief from standard creams.


Here's Why Incyte (INCY) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Opzelura (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate...

Incyte Says It's No Longer A One-Drug Story

Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.read more...

INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised

Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.

Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported an increase in second-quarter earnings and revenue, driven by strong growth across its commercial portfolio. The company also raised its full-year 2026 sales guidance...

James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition

James Michael Morrissey, EVP at Incyte (NASDAQ:INCY), reported acquisition of company stock options on July 27, according to a new SEC filing.
What Happened: Uncovered in a Form 4 filing on Monday with the U.S.read more...

A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options

In a new SEC filing on July 27, it was unveiled that Heeson, EVP at Incyte (NASDAQ:INCY), acquired stock options for 15,423 shares.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission onread more...

$INCY Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $2.92 up 39.71% YoY
• Reported revenue of $1.67B up 37.72% YoY
• Incyte is raising its fiscal year 2026 total net sales guidance to $5,130 - $5,260 million, while total GAAP R&D and SG&A operating expense guidance is $4,915 - $4,995 million.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$119.52
Prev Close	$122.99
Open	$122.75
Dividend Yield	0.00%
50-Day Moving Average	$109.13
Beta	0.52
Avg. Volume	2.24M
PE Ratio	15.23

52-Week High	$132.60
52-Week Low	$75.48
Market Capitalization	$24.23B
EPS (Annual)	$6.41
Price to Book	3.79
Revenue Per Employee	$1.81M

Feed

News

Sentiment

Earnings

Fundamentals

Info